暴露式家庭治疗降低青少年共病物质使用问题与PTSD症状的安全性与疗效:一项随机临床试验
该随机临床试验纳入124名13-18岁、过去90天内有非烟草物质使用、至少1次人际创伤事件且PTSD症状≥5条的青少年,比较暴露式整合干预RRFT与常规治疗TAU。RRFT组在12和18个月时物质使用天数显著少于TAU组,两组PTSD症状均组内改善但组间无差异,未观察到物质使用恶化。
要点
- RRFT在减少青少年非烟草物质使用天数上优于以创伤聚焦CBT为主的TAU。
- 两组PTSD症状均显著改善,但组间差异未达显著。
- 暴露式治疗未导致物质使用恶化,提示对共病青少年安全可行。
核心结论
- RRFT与TAU均使青少年物质使用问题和PTSD症状组内改善,RRFT在物质使用及PTSD回避、高唤醒症状上改善更明显。
- 未观察到任一条件下物质使用恶化,提示暴露式治疗对共病青少年安全、可由社区临床医生可行地实施。
研究设计与样本
- 随机临床试验,2012年11月1日至2017年1月30日招募124名13-18岁青少年,随机接受RRFT(n=61)或TAU(n=63)。
- 入组条件为过去90天内至少1次非烟草物质使用、至少1次人际创伤事件、PTSD症状≥5条;在美国东南部社区儿童权益中心开展,盲法评估于基线及3、6、12、18个月进行,按意向性分析。
主要发现
- 相较TAU,RRFT从基线至12个月(事件率0.28;95%CI 0.12-0.65)和18个月(事件率0.10;95%CI 0.04-0.24)物质使用天数显著减少。
- RRFT组PTSD症状从基线至3、6、12、18个月均显著下降(β分别为-9.25、-16.63、-17.51、-19.02)。
- TAU组PTSD症状从基线至3、6、12、18个月亦显著下降(β分别为-9.62、-13.73、-15.53、-13.88),但组间差异未观察到。
关键数值与推荐
- 主要结局为时间线回溯法测量的非烟草物质使用天数,以及青少年和照护者完成的UCLA PTSD反应指数(DSM-IV)评估的PTSD症状严重度。
- 次要结局包括大麻、酒精和多物质使用及PTSD再体验、回避、高唤醒症状严重度。
临床怎么用
- 对于共病物质使用问题与PTSD症状的青少年,可考虑由社区临床医生实施暴露式整合家庭治疗RRFT。
- 暴露式PTSD治疗未导致物质使用恶化,临床不应因共病物质使用而常规回避暴露干预。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: No empirically supported treatments have been evaluated to address co-occurring substance use problems (SUP) and posttraumatic stress disorder (PTSD) symptoms among adolescents in an integrative fashion. This lack is partially owing to untested clinical lore suggesting that delivery of exposure-based PTSD treatments to youth with SUP might be iatrogenic. OBJECTIVE: To determine whether an exposure-based, integrative intervention for adolescents with SUP and PTSD symptoms-risk reduction through family therapy (RRFT)-resulted in improved outcomes relative to a treatment-as-usual (TAU) control condition consisting primarily of trauma-focused cognitive behavioral therapy. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled 124 participants who were recruited from November 1, 2012, through January 30, 2017. Adolescents (aged 13-18 years) who engaged in nontobacco substance use at least once during the past 90 days, experienced at least 1 interpersonal traumatic event, and reported 5 or more PTSD symptoms were enrolled. Blinded assessments were collected at baseline and at 3, 6, 12, and 18 months after baseline. Recruitment and treatment took place in community-based child advocacy centers in the Southeastern United States. Data were analyzed from August 2 through October 4, 2018, and were based on intention to treat. INTERVENTIONS: Participants were randomized to receive RRFT (n = 61) or TAU (n = 63). MAIN OUTCOMES AND MEASURES: Primary outcomes focused on number of nontobacco substance-using days measured with the timeline follow-back method and PTSD symptom severity using the UCLA (University of California, Los Angeles) PTSD Reaction Index for DSM-IV completed by adolescents and caregivers. Secondary outcomes focused on marijuana, alcohol, and polysubstance use and PTSD criterion standard (re-experiencing, avoidance, and hyperarousal) symptom severity. RESULTS: In all, 124 adolescents (mean [SD] age, 15.4 [1.3] years; 108 female [87.1%]) were randomized. For primary outcomes relative to TAU, RRFT yielded significantly greater reductions in substance-using days from baseline to month 12 (event rate [ER], 0.28; 95% CI, 0.12-0.65) and month 18 (ER, 0.10; 95% CI, 0.04-0.24). Significant reductions in PTSD symptoms were observed within groups for RRFT from baseline to months 3 (β = -9.25; 95% CI, -12.95 to -5.55), 6 (β = -16.63; 95% CI = -20.40 to -12.87), 12 (β = -17.51; 95% CI, -21.62 to -13.40), and 18 (β = -19.02; 95% CI, -23.07 to -14.96) and for TAU from baseline to months 3 (β = -9.62; 95% CI, -13.16 to -6.08), 6 (β = -13.73; 95% CI, -17.43 to -10.03), 12 (β = -15.53; 95% CI, -19.52 to -11.55), and 18 (β = -13.88; 95% CI, -17.69 to -10.09); however, between-group differences were not observed. CONCLUSIONS AND RELEVANCE: In this study, RRFT and TAU demonstrated within-group improvements in SUP and PTSD symptoms, with greater improvement for substance use and PTSD avoidance and hyperarousal symptoms among adolescents randomized to RRFT compared with TAU. No evidence of the worsening of SUP was observed in either condition. These results suggest that this exposure-based treatment is safe, feasibly delivered by community-based clinicians, and offers an effective approach to inform clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01751035.
引用
- Danielson CK, Adams Z, McCart MR, et al. Safety and Efficacy of Exposure-Based Risk Reduction Through Family Therapy for Co-occurring Substance Use Problems and Posttraumatic Stress Disorder Symptoms Among Adolescents: A Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 32022827. doi:10.1001/jamapsychiatry.2019.4803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。